On the One Show last night David Noakes, CEO of Immuno Biotech Ltd, made some very bold claims that a treatment called GcMaf can cure stage four pancreatic cancer as well autism. This is despite the fact the drug, labelled as 'First Immune,' is not licensed and has not been tested for quality, safety or effectiveness.
The BBC has reported it as ‘controversial in cancer research circles’.
Alex Ford, Chief Executive of Pancreatic Cancer UK, comments,
“We are shocked to learn that David Noakes, who has no medical training, is making such dangerous claims that GcMaf can cure pancreatic cancer. There is absolutely no evidence that supports this.
“Pancreatic cancer has the worst survival rate of any of the most common cancers - something that’s hardly changed in over 40 years. We know first hand the devastation this lethal disease leaves in its wake, which is why one of our priorities is to fund innovative research, including in the area of immunotherapy.
People with pancreatic cancer don’t need bogus medicine giving false hope, they need new, effective treatments.”